肺癌義診計劃
申請日期：即日起至2024年12月31日
名額：每月10位（額滿即止）
對象：新確診的肺癌病人
乳癌義診計劃
申請日期：即日起至2024年12月31日
名額：每月10位（額滿即止）
對象：已擴散的乳癌病人
ABOUT US/關於我們
The society is established for objectives and purposes as follows: To promote education and exchange of knowledge in the fields of solid tumours.To facilitate research for improving the knowledge of solid tumours.To endeavor to improve the standard of care for patients with solid tumours.To organise scientific and social meetings in order to encourage interchange of knowledge and to stimulate co-operation in the management, control and treatment of various solid tumours.
NGS CONSORTIUM/次世代基因聯盟
We connect all commercially available laboratories that offer state-of-art next-generation sequencing technology
Science Park, HONG KONG
The name ‘Sanomics’ is derived from the word of Sanguis, the Latin word for blood, and genomics, which stands for the study of genes.
Since the launch of Sanomics, “Patient First” has always been our principle. Putting patients’ needs as our top priority, we strive to revolutionize current cancer treatments by providing safe and efficient liquid-based and tissue-based genomic tests to patients. We aim to provide easy and convenient access to our services and help doctors decide personalized cancer solutions for patients.
Boston, USA
Our work offers more than information; it can inspire hope in patients, families, friends, physicians, and caregivers.
Through constant innovation, we can make breakthroughs to help achieve improved outcomes for more individuals living with cancer. That’s why we foster a collaborative culture that motivates us to do our best work and be a partner in every patient's journey.
Our approach combines genomic profile products and data services to generate insights that can help doctors match patients to more treatment options and help accelerate the development of new therapies.
Taipei, TAIWAN
ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings, we are dedicated to turning every cancer patient’s genetic information into actionable resolutions.
UPCOMING EVENTS 最新活動
